carbostyril has been researched along with Behavior Disorders in 46 studies
| Timeframe | Studies, this research(%) | All Research% |
|---|---|---|
| pre-1990 | 0 (0.00) | 18.7374 |
| 1990's | 0 (0.00) | 18.2507 |
| 2000's | 23 (50.00) | 29.6817 |
| 2010's | 22 (47.83) | 24.3611 |
| 2020's | 1 (2.17) | 2.80 |
| Authors | Studies |
|---|---|
| Banner, J; Johansen, SS; Linnet, K; Rygaard, K | 1 |
| Allavena, C; Bani-Sadr, F; Bregigeon, S; Cabié, A; Cuzin, L; Ferry, T; Katlama, C; Lourenco, J; Pugliese, P; Rey, D; Reynes, J | 1 |
| Bitter, I; Corponi, F; Fabbri, C; Kasper, S; Montgomery, S; Pallanti, S; Serretti, A; Vieta, E | 1 |
| Fraile, S; García, B; Hidalgo, FJ; Lopez, E | 1 |
| Fuller, C; Grudziak, J; Nguyen, HL; Rickels, K; Rickels, MR; Teff, KL | 1 |
| Calabrò, MP; D'Amico, G; Gagliano, A; Germanò, E; Guerriero, L; Ingrassia, M; Italiano, D; Lamberti, M; Privitera, C; Siracusano, R; Spina, E | 1 |
| Arshad, E; Deb, S; Deb, T; Farmah, BK; Roy, M; Unwin, GL | 1 |
| Kagawa, S; Kondo, T; Mihara, K; Nagai, G; Nakamura, A; Nemoto, K; Suzuki, T | 1 |
| Himle, M; Schrock, L; Shprecher, DR | 1 |
| Howland, RH | 1 |
| Kibble, A | 1 |
| Citrome, L; Maeda, K; Stensbøl, TB | 1 |
| Panayiotakopoulos, G; Zareifopoulos, N | 1 |
| Azorin, JM; Camus, V; Costentin, J; Crocq, MA; Daléry, J; Gliskman, J; Krebs, MO; Limosin, F; Millet, B | 1 |
| Anderson, SJ; Brady, KT; McRae, AL; Tolliver, BK; Verduin, ML | 1 |
| Barbero, JD; Benito, N; Cobo Gómez, JV; Coronas, R; Domenech, C; Fuste, G; García-Parés, G; Gómez, JV | 1 |
| Bahk, WM; Cho, JY; Jang, IJ; Kang, DH; Kim, JR; Kim, YK; Kwon, JS; Seo, HB; Shin, SG; Yu, KS | 1 |
| Bies, R; Devlin, B; Dew, MA; Driscoll, HC; Lenze, EJ; Lotrich, F; Mulsant, BH; Pollock, BG; Reynolds, CF; Sheffrin, M | 1 |
| Coley, KC; Fabian, TJ; Lenze, EJ; Ruby, C; Scipio, TM | 1 |
| Price, LH | 1 |
| DeLorenze, G; L'Italien, G; McQuade, R; Newcomer, J; Oliveria, SA; Quesenberry, CP; Tsai, AL; Willey, VJ; Yood, MU | 1 |
| Helm, ME; Henderson, C; Martin, BC; Pathak, P; West, D | 1 |
| Aitchison, KJ; McAllister, VD; McCrone, P; Mir, A; O'Keane, V; Shivakumar, K | 1 |
| Bhutani, T; Busse, KL; Koo, JY; Ladizinski, B | 1 |
| Katzman, MA | 1 |
| Filipe, A; Tomé, AM | 1 |
| Diaz-Atienza, F; Gurpegui, M; Gutiérrez-Rojas, L; Jurado, D; Martínez-Ortega, JM | 1 |
| Capote, E; Ezequiel, U; Paez, R; Wix-Ramos, RJ | 1 |
| Chaumartin, N; Lachaux, B; Monville, M | 1 |
| de Andrés, F; de la Rubia, A; Dorado, P; González, AP; González, I; Llerena, A; Naranjo, ME; Peñas-Lledó, EM | 1 |
| Attademo, L; Moretti, P; Quartesan, R | 1 |
| Goodnick, PJ; Jerry, JM | 1 |
| Ismail, MS; Profenno, LA; Tariot, PN | 1 |
| Citrome, L; Volavka, J | 1 |
| Aubry, JM; Bertschy, G; Bryois, C; Eliez, S; Etter, M; Nanzer, N | 1 |
| Burns, T; Dursun, S; Fahy, T; Frangou, S; Gray, R; Haddad, PM; Hunter, R; Taylor, DM; Travis, MJ; Young, AH | 1 |
| López-Meza, E; Ramirez-Bermudez, J; Ruiz-Chow, A | 1 |
| Kim, TS; Lee, C; Pae, CU; Paik, IH | 1 |
| Ballard, C; Waite, J | 1 |
| Alla, L; Sabaratnam, M; Shastri, M | 1 |
| Crismon, ML; Fischer, C; Gibson, AP; Mican, LM | 1 |
| Brahm, NC; Brown, RC; McElwain, DL | 1 |
| Chiu, HJ; Hu, TM; Huang, HC; Lan, TH; Liu, CH; Tseng, YL; Wu, YC | 1 |
| Wooten, J | 1 |
| Mago, R | 1 |
16 review(s) available for carbostyril and Behavior Disorders
| Article | Year |
|---|---|
Novel antipsychotics specificity profile: A clinically oriented review of lurasidone, brexpiprazole, cariprazine and lumateperone.
Topics: Animals; Antipsychotic Agents; Heterocyclic Compounds, 4 or More Rings; Humans; Lurasidone Hydrochloride; Mental Disorders; Piperazines; Quinolones; Thiophenes | 2019 |
The effectiveness of aripiprazole in the management of problem behaviour in people with intellectual disabilities, developmental disabilities and/or autistic spectrum disorder--a systematic review.
Topics: Aggression; Antipsychotic Agents; Aripiprazole; Child Development Disorders, Pervasive; Developmental Disabilities; Humans; Intellectual Disability; Mental Disorders; Piperazines; Quinolones; Self-Injurious Behavior; Treatment Outcome | 2014 |
Neurobehavioral aspects, pathophysiology, and management of Tourette syndrome.
Topics: Alcohol Oxidoreductases; Aripiprazole; Benzazepines; Cerebellar Nuclei; Disease Management; Dopamine Antagonists; Humans; Mental Disorders; Mutation; Piperazines; Quinolones; Tourette Syndrome | 2014 |
The preclinical profile of brexpiprazole: what is its clinical relevance for the treatment of psychiatric disorders?
Topics: Animals; Clinical Trials, Phase III as Topic; Drug Evaluation, Preclinical; Humans; Mental Disorders; Quinolones; Randomized Controlled Trials as Topic; Thiophenes | 2015 |
Neuropsychiatric Effects of Antimicrobial Agents.
Topics: Aminoglycosides; Anti-Bacterial Agents; Anti-Infective Agents; GABA-A Receptor Agonists; Humans; Mental Disorders; Monoamine Oxidase Inhibitors; Quinolones | 2017 |
[Clinical potentialities and perspectives for the use of aripiprazole in other disorders than its classical indications. A critical analysis of the recent literature].
Topics: Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Borderline Personality Disorder; Depressive Disorder, Major; Humans; Mental Disorders; Neurodegenerative Diseases; Parkinson Disease; Piperazines; Quinolones; Schizophrenia; Substance-Related Disorders; Tourette Syndrome | 2008 |
Incomplete response in late-life depression: getting to remission.
Topics: Aged; Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Depressive Disorder; Drug Therapy, Combination; Humans; Mental Disorders; Piperazines; Quinolones; Treatment Outcome | 2008 |
Aripiprazole: a clinical review of its use for the treatment of anxiety disorders and anxiety as a comorbidity in mental illness.
Topics: Anti-Anxiety Agents; Antipsychotic Agents; Anxiety; Anxiety Disorders; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Drug Therapy, Combination; Humans; Mental Disorders; Piperazines; Quinolones | 2011 |
Quinolones: review of psychiatric and neurological adverse reactions.
Topics: Animals; Anti-Bacterial Agents; Humans; Mental Disorders; Nervous System Diseases; Quinolones | 2011 |
Aripiprazole: profile on efficacy and safety.
Topics: Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Brain; Cardiovascular System; Clinical Trials as Topic; Digestive System; Dyskinesia, Drug-Induced; Humans; Mental Disorders; Piperazines; Quinolones; Schizophrenia | 2002 |
Efficacy of atypical antipsychotics in elderly patients with dementia.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Basal Ganglia Diseases; Benzodiazepines; Brief Psychiatric Rating Scale; Controlled Clinical Trials as Topic; Dementia; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Treatment Outcome | 2004 |
The promise of atypical antipsychotics: fewer side effects mean enhanced compliance and improved functioning.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus, Type 2; Dibenzothiazepines; Drug Administration Schedule; Humans; Hyperprolactinemia; Mental Disorders; Olanzapine; Patient Compliance; Piperazines; Practice Guidelines as Topic; Prescription Fees; Quetiapine Fumarate; Quinolones; Risk Assessment; Risperidone; Thiazoles; Torsades de Pointes; Treatment Outcome; Weight Gain | 2004 |
[Psychiatry].
Topics: Antidepressive Agents; Antipsychotic Agents; Aripiprazole; Attention Deficit Disorder with Hyperactivity; Humans; Lamotrigine; Mental Disorders; Methylphenidate; Piperazines; Quinolones; Risperidone; Triazines | 2005 |
The effectiveness of atypical antipsychotics for the treatment of aggression and psychosis in Alzheimer's disease.
Topics: Aggression; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Dibenzothiazepines; Humans; Mental Disorders; Olanzapine; Piperazines; Psychomotor Agitation; Psychotic Disorders; Quetiapine Fumarate; Quinolones; Randomized Controlled Trials as Topic; Risperidone | 2006 |
Metabolic effects of the atypical antipsychotics.
Topics: Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Diabetes Mellitus; Dibenzothiazepines; Dyslipidemias; Glucose Metabolism Disorders; Humans; Insulin Resistance; Mental Disorders; Obesity; Olanzapine; Phenothiazines; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Thiazoles | 2007 |
Proposed strategies for successful clinical management with aripiprazole.
Topics: Antipsychotic Agents; Aripiprazole; Clinical Trials as Topic; Dose-Response Relationship, Drug; Drug Administration Schedule; Humans; Mental Disorders; Piperazines; Practice Guidelines as Topic; Quinolones; Titrimetry; Treatment Outcome | 2008 |
6 trial(s) available for carbostyril and Behavior Disorders
| Article | Year |
|---|---|
Antipsychotic-induced insulin resistance and postprandial hormonal dysregulation independent of weight gain or psychiatric disease.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Eating; Female; Humans; Insulin Resistance; Male; Mental Disorders; Olanzapine; Piperazines; Postprandial Period; Quinolones; Weight Gain; Young Adult | 2013 |
Effects of escitalopram on plasma concentrations of aripiprazole and its active metabolite, dehydroaripiprazole, in Japanese patients.
Topics: Adult; Aripiprazole; Asian People; Citalopram; Cytochrome P-450 CYP2C19; Cytochrome P-450 CYP2D6; Drug Therapy, Combination; Electrocardiography; Electroencephalography; Female; Genotype; Humans; Male; Mental Disorders; Middle Aged; Paroxetine; Piperazines; Quinolones | 2014 |
Population pharmacokinetic modelling of aripiprazole and its active metabolite, dehydroaripiprazole, in psychiatric patients.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cytochrome P-450 CYP2D6; Drug Interactions; Drug Monitoring; Female; Genotype; Humans; Male; Mental Disorders; Metabolic Clearance Rate; Middle Aged; Models, Biological; Piperazines; Polymorphism, Genetic; Quinolones; Young Adult | 2008 |
Aripiprazole prescribing patterns and side effects in elderly psychiatric inpatients.
Topics: Aged; Aged, 80 and over; Aging; Antipsychotic Agents; Aripiprazole; Bipolar Disorder; Depressive Disorder, Major; Dose-Response Relationship, Drug; Female; Humans; Inpatients; Male; Mental Disorders; Middle Aged; Piperazines; Psychiatric Status Rating Scales; Psychomotor Agitation; Psychotic Disorders; Quinolones; Retrospective Studies; Schizophrenia; Treatment Outcome | 2009 |
Costs and outcomes associated with an aripiprazole add-on or switching open-label study in psychosis.
Topics: Adolescent; Adult; Antipsychotic Agents; Aripiprazole; Cost-Benefit Analysis; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Middle Aged; Piperazines; Quality of Life; Quinolones; Time Factors; Treatment Outcome; Young Adult | 2011 |
High-performance liquid chromatography method using ultraviolet detection for the quantification of aripiprazole and dehydroaripiprazole in psychiatric patients.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Drug Monitoring; Female; Humans; Limit of Detection; Male; Mental Disorders; Middle Aged; Piperazines; Quinolones; Reproducibility of Results; Spectrophotometry, Ultraviolet | 2012 |
24 other study(ies) available for carbostyril and Behavior Disorders
| Article | Year |
|---|---|
Concentrations of aripiprazole and dehydroaripiprazole in hair segments from deceased individuals with mental disorders.
Topics: Adult; Aged; Antipsychotic Agents; Aripiprazole; Chromatography, High Pressure Liquid; Female; Forensic Toxicology; Hair; Humans; Male; Mental Disorders; Middle Aged; Piperazines; Polypharmacy; Postmortem Changes; Quinolones; Tandem Mass Spectrometry; Young Adult | 2020 |
Integrase strand transfer inhibitors and neuropsychiatric adverse events in a large prospective cohort.
Topics: Antiretroviral Therapy, Highly Active; CD4 Lymphocyte Count; Cohort Studies; Female; France; Heterocyclic Compounds, 3-Ring; HIV Infections; HIV Integrase Inhibitors; Humans; Male; Mental Disorders; Nervous System Diseases; Oxazines; Piperazines; Prospective Studies; Public Health Surveillance; Pyridones; Quinolones; Raltegravir Potassium; Viral Load | 2019 |
[Possible malignant neuroleptic syndrome associated with aripiprazole and imipramine and treated with bromocriptine].
Topics: Antipsychotic Agents; Aripiprazole; Bromocriptine; Combined Modality Therapy; Drug Therapy, Combination; Emergencies; Frontotemporal Dementia; Humans; Imipramine; Lorazepam; Male; Mental Disorders; Middle Aged; Neuroleptic Malignant Syndrome; Oxygen Inhalation Therapy; Piperazines; Quinolones; Respiration, Artificial; Respiratory Insufficiency | 2013 |
ECG parameters in children and adolescents treated with aripiprazole and risperidone.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Child, Preschool; Electrocardiography; Female; Heart Rate; Humans; Male; Mental Disorders; Piperazines; Prospective Studies; Quinolones; Retrospective Studies; Risperidone | 2014 |
Atypical antipsychotics are not all alike: side effects and risk assessment.
Topics: Antipsychotic Agents; Aripiprazole; Decision Making; Humans; Mental Disorders; Off-Label Use; Patient Education as Topic; Piperazines; Quinolones; Risk Assessment; Risperidone | 2014 |
American Psychiatric Association - 168th Annual Meeting (May 16-20, 2015 - Toronto, Canada).
Topics: Alcoholism; Benzofurans; Canada; Drug Discovery; Humans; Indoles; Mental Disorders; Piperazines; Psychiatry; Quinolones; Schizophrenia; Thiophenes; Vilazodone Hydrochloride | 2015 |
Reversible elevation of triglycerides in dual-diagnosis patients taking aripiprazole: a case series.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Diagnosis, Dual (Psychiatry); Humans; Hypertriglyceridemia; Mental Disorders; Piperazines; Quinolones; Substance-Related Disorders; Triglycerides; Weight Gain | 2008 |
Combination of aripiprazole and other psychopharmacological treatments in resistant and multi-resistant patients.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Drug Resistance; Drug Resistance, Multiple; Drug Therapy, Combination; Female; Humans; Male; Mental Disorders; Middle Aged; Obsessive-Compulsive Disorder; Outcome Assessment, Health Care; Personality Disorders; Piperazines; Psychotropic Drugs; Quinolones; Retrospective Studies; Schizophrenia; Spain | 2008 |
Atypical antipsychotic drugs and the risk of sudden cardiac death.
Topics: Antipsychotic Agents; Aripiprazole; Death, Sudden, Cardiac; Dose-Response Relationship, Drug; Humans; Mental Disorders; Piperazines; Quinolones; Risk; Thiazoles | 2009 |
The incidence of diabetes in atypical antipsychotic users differs according to agent--results from a multisite epidemiologic study.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Clozapine; Cohort Studies; Diabetes Mellitus; Female; Humans; Male; Mental Disorders; Middle Aged; Olanzapine; Piperazines; Quinolones; Retrospective Studies; Thiazoles; United States | 2009 |
Evidence-based use of second-generation antipsychotics in a state Medicaid pediatric population, 2001-2005.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Benzodiazepines; Child; Child, Preschool; Clozapine; Dibenzothiazepines; Drug Utilization; Evidence-Based Medicine; Female; Humans; Infant; Insurance Claim Review; Male; Medicaid; Mental Disorders; Off-Label Use; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Thiazoles; United States; United States Food and Drug Administration | 2010 |
Aripiprazole as a viable alternative for treating delusions of parasitosis.
Topics: Aged, 80 and over; Antipsychotic Agents; Aripiprazole; Delusions; Female; Humans; Mental Disorders; Movement Disorders; Parasitic Diseases; Pimozide; Piperazines; Quinolones; Risperidone | 2010 |
Confounding by indication of a specific antipsychotic and the increase of body mass index among children and adolescents.
Topics: Adolescent; Analysis of Variance; Antipsychotic Agents; Aripiprazole; Attention Deficit and Disruptive Behavior Disorders; Benzodiazepines; Bipolar Disorder; Body Mass Index; Body Weight; Child; Dibenzothiazepines; Female; Follow-Up Studies; Humans; Male; Mental Disorders; Olanzapine; Piperazines; Quetiapine Fumarate; Quinolones; Risperidone; Schizophrenia; Spain; Time Factors | 2011 |
Pituitary microadenoma treated with antipsychotic drug aripiprazole.
Topics: Adenoma; Adult; Antipsychotic Agents; Aripiprazole; Drug Partial Agonism; Humans; Male; Mental Disorders; Piperazines; Pituitary Neoplasms; Quinolones; Receptors, Dopamine D2 | 2011 |
[Dysphagia or dysphagias during neuroleptic medication?].
Topics: Adult; Anticonvulsants; Antipsychotic Agents; Aripiprazole; Clonazepam; Deglutition Disorders; Diagnosis, Differential; Dose-Response Relationship, Drug; Drug Substitution; Drug Therapy, Combination; Homicide; Humans; Ill-Housed Persons; Loxapine; Male; Mental Disorders; Piperazines; Quinolones; Risk Factors; Schizophrenia; Schizophrenic Psychology | 2012 |
[Efficacy of aripiprazole on cognitive and behavioral changes in a young woman with systemic lupus erythematosus].
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Cognition Disorders; Female; Humans; Lupus Erythematosus, Systemic; Mental Disorders; Piperazines; Quinolones | 2012 |
Medication developments in the treatment of mental illness.
Topics: Adolescent; Aged; Alzheimer Disease; Antipsychotic Agents; Aripiprazole; Blood Glucose; Child; Depressive Disorder; Humans; Mental Disorders; Piperazines; Primary Health Care; Quinolones; Schizophrenia; Selective Serotonin Reuptake Inhibitors | 2003 |
Aripiprazole in schizophrenia: consensus guidelines.
Topics: Antipsychotic Agents; Aripiprazole; Consensus; Drug Interactions; Heart Diseases; Humans; Hypertension; Mental Disorders; Metabolic Diseases; Patient Compliance; Piperazines; Quinolones; Schizophrenia; Treatment Outcome | 2005 |
Aripiprazole in psychosis associated with Parkinson's disease.
Topics: Aged; Antipsychotic Agents; Aripiprazole; Female; Humans; Male; Mental Disorders; Middle Aged; Parkinson Disease; Piperazines; Psychiatric Status Rating Scales; Quinolones | 2005 |
Effect of aripiprazole for a patient with psychotic symptoms and parkinsonism associated with delayed-sequelae of carbon monoxide intoxication.
Topics: Adult; Antipsychotic Agents; Aripiprazole; Carbon Monoxide Poisoning; Female; Humans; Mental Disorders; Parkinsonian Disorders; Piperazines; Quinolones | 2005 |
Aripiprazole use in individuals with intellectual disability and psychotic or behavioural disorders: a case series.
Topics: Adolescent; Aged; Antipsychotic Agents; Aripiprazole; Autistic Disorder; Female; Humans; Intellectual Disability; Male; Mental Disorders; Middle Aged; Piperazines; Psychotic Disorders; Quinolones; Schizophrenia; Schizophrenia, Paranoid | 2006 |
Effectiveness and tolerability of aripiprazole in child and adolescent inpatients: a retrospective evaluation.
Topics: Adolescent; Antipsychotic Agents; Aripiprazole; Child; Clinical Trials as Topic; Female; Humans; Inpatients; Male; Mental Disorders; Piperazines; Psychiatric Status Rating Scales; Quinolones; Retrospective Studies; Treatment Outcome | 2007 |
Potential aripiprazole-mediated extrapyramidal symptoms in an adult with developmental disabilities.
Topics: Adult; Algorithms; Antipsychotic Agents; Aripiprazole; Baclofen; Basal Ganglia Diseases; Citalopram; Diphenhydramine; Drug Interactions; Dyskinesia, Drug-Induced; Humans; Hypnotics and Sedatives; Male; Mental Disorders; Oxazepam; Piperazines; Quinolones | 2007 |
Detection and quantification of aripiprazole and its metabolite, dehydroaripiprazole, by gas chromatography-mass spectrometry in blood samples of psychiatric patients.
Topics: Antipsychotic Agents; Aripiprazole; Gas Chromatography-Mass Spectrometry; Humans; Mental Disorders; Piperazines; Quinolones; Reference Standards; Sensitivity and Specificity | 2007 |